Alcon Inc./Fr. ALC
1D1W1MYTD1Y5YMAX
Capital at risk
About Alcon Inc.
Alcon Inc. is a global company specializing in eye care products and medical devices, serving the healthcare sector. The company focuses on two main divisions: Surgical and Vision Care. Its Surgical segment offers ophthalmic products such as cataract, retinal, and refractive surgery equipment, while the Vision Care segment provides contact lenses and lens care products. Headquartered in Geneva, Switzerland, Alcon was founded in 1945 as a small ophthalmic shop in Texas and has since expanded its footprint internationally. Alcon benefits from its extensive research and development capabilities, underpinned by a robust portfolio of market-driven innovations aiming to address unmet eye care needs globally.
- Ticker
- Fr. ALC
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 25,000
- Headquarters
- Geneva, Switzerland
- Website
- www.alcon.com
Alcon Inc. Metrics
BasicAdvanced
CHF 26B
50.30
CHF 1.07
0.69
CHF 0.28
0.52%
Price and volume
Market cap
CHF 26B
Beta
0.69
52-week high
CHF 68.34
52-week low
CHF 47.80
Average daily volume
1.1M
Dividend rate
CHF 0.28
Financial strength
Current ratio
2.092
Quick ratio
1.123
Long term debt to equity
21.523
Total debt to equity
24.537
Dividend payout ratio (TTM)
27.06%
Interest coverage (TTM)
6.69%
Profitability
EBITDA (TTM)
1,963.106
Gross margin (TTM)
57.22%
Net profit margin (TTM)
5.92%
Operating margin (TTM)
12.88%
Effective tax rate (TTM)
13.23%
Revenue per employee (TTM)
CHF 351,130
Management effectiveness
Return on assets (TTM)
2.80%
Return on equity (TTM)
2.94%
Valuation
Price to earnings (TTM)
50.299
Price to revenue (TTM)
2.972
Price to book
1.21
Price to tangible book (TTM)
6.42
Price to free cash flow (TTM)
20.315
Free cash flow yield (TTM)
4.92%
Free cash flow per share (TTM)
2.653
Dividend yield (TTM)
0.52%
Forward dividend yield
0.52%
Growth
Revenue change (TTM)
8.34%
Earnings per share change (TTM)
-39.24%
3-year revenue growth (CAGR)
6.13%
3-year earnings per share growth (CAGR)
21.53%
3-year dividend per share growth (CAGR)
15.85%
Bulls say / Bears say
Q2 2026 sales rose 8% reported and 7% at constant currency to $2.8 billion, while management raised full-year core operating-margin and core EPS-growth guidance. (SEC)
New products—including Unity, PanOptix Pro, Tryptyr and Precision7—are driving growth across Surgical and Vision Care, with Q1 sales up 6% at constant currency and Q2 momentum continuing. (SEC)
Alcon is expanding its innovation and commercial ecosystem through its July 2026 collaboration with RxSight to develop adjustable posterior-chamber intraocular lenses, potentially strengthening its longer-term premium-surgery pipeline. (Alcon)
Alcon recorded a $505 million non-cash impairment charge in Q2 2026 after discontinuing its PowerVision programs, highlighting execution risk in its internal innovation pipeline. (SEC)
Tariffs remain a meaningful earnings headwind: Alcon incurred $39 million of tariff costs in the first half of 2026 and expects a full-year net impact of approximately $40 million to $90 million. (SEC)
Alcon’s August 2026 issuance of €500 million in senior notes increases leverage and future interest obligations, potentially limiting financial flexibility despite ongoing buybacks. (Alcon)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Upcoming events
No upcoming events
Funds containing Alcon Inc.
AllEURGBPUSD
Fund name | Fund size | Fr. ALC weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector€ESIH | €863M | 1.83% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 1.83% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 1.82% |
iShares MSCI Europe SRI€IESE | €3.1B | 1.34% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 1.25% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.